These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 1363928)

  • 21. Comparative behavioural effects of benzodiazepine and non-benzodiazepine anxiolytics in rhesus monkeys.
    Kumar R; Palit G; Singh JR; Dhawan BN
    Pharmacol Res; 1999 Jun; 39(6):437-44. PubMed ID: 10373237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-N-methyl-D-aspartate receptor antagonism by 3-N-substituted 2,3-benzodiazepines: relationship to anticonvulsant activity.
    Donevan SD; Yamaguchi S; Rogawski MA
    J Pharmacol Exp Ther; 1994 Oct; 271(1):25-9. PubMed ID: 7525924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the effects of typical and atypical anxiolytics on learning in monkeys and rats.
    Winsauer PJ; Bixler MA; Mele PC
    J Pharmacol Exp Ther; 1996 Mar; 276(3):1111-27. PubMed ID: 8786542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pituitary-adrenal axis and the different behavioral effects of buspirone and chlordiazepoxide.
    McNaughton N; Panickar KS; Logan B
    Pharmacol Biochem Behav; 1996 May; 54(1):51-6. PubMed ID: 8728538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The NK1 receptor antagonist NKP608 lacks anxiolytic-like activity in Swiss-Webster mice exposed to the elevated plus-maze.
    Rodgers RJ; Gentsch C; Hoyer D; Bryant E; Green AJ; Kolokotroni KZ; Martin JL
    Behav Brain Res; 2004 Sep; 154(1):183-92. PubMed ID: 15302124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Buspirone, chlordiazepoxide and diazepam effects in a zebrafish model of anxiety.
    Bencan Z; Sledge D; Levin ED
    Pharmacol Biochem Behav; 2009 Nov; 94(1):75-80. PubMed ID: 19643124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of propranolol, buspirone, pCPA, reserpine, and chlordiazepoxide on open-field behavior.
    Angrini M; Leslie JC; Shephard RA
    Pharmacol Biochem Behav; 1998 Feb; 59(2):387-97. PubMed ID: 9476986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of buspirone and chlordiazepoxide in the shock-probe/burying test for anxiolytics.
    Treit D; Fundytus M
    Pharmacol Biochem Behav; 1988 Aug; 30(4):1071-5. PubMed ID: 3227031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of buspirone on the behavioral regulation of rats in low versus high anxiety conditions.
    Lim LW; Temel Y; Visser-Vandewalle V; Steinbusch H; Schruers K; Hameleers R; Esquivel G; Griez E; Blokland A
    Arzneimittelforschung; 2008; 58(6):269-76. PubMed ID: 18677968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of Echinacea preparations in three laboratory tests of anxiety: comparison with chlordiazepoxide.
    Haller J; Hohmann J; Freund TF
    Phytother Res; 2010 Nov; 24(11):1605-13. PubMed ID: 21031616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The shock probe conflict procedure. A new assay responsive to benzodiazepines, barbiturates and related compounds.
    Meert TF; Colpaert FC
    Psychopharmacology (Berl); 1986; 88(4):445-50. PubMed ID: 2871580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anxiolytic effects of the novel anti-epileptic drug levetiracetam in the elevated plus-maze test in the rat.
    Gower AJ; Falter U; Lamberty Y
    Eur J Pharmacol; 2003 Nov; 481(1):67-74. PubMed ID: 14637176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat.
    Pellow S; File SE
    Pharmacol Biochem Behav; 1986 Mar; 24(3):525-9. PubMed ID: 2871560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of chlordiazepoxide, bretazenil, L838,417 and zolpidem in a validated mouse Vogel conflict test.
    Mathiasen L; Mirza NR
    Psychopharmacology (Berl); 2005 Nov; 182(4):475-84. PubMed ID: 16133136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The anxiolytic CRF(1) antagonist DMP696 fails to function as a discriminative stimulus and does not substitute for chlordiazepoxide in rats.
    Lelas S; Zeller KL; Ward KA; McElroy JF
    Psychopharmacology (Berl); 2003 Apr; 166(4):408-15. PubMed ID: 12590355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological properties of tracazolate: a new non-benzodiazepine anxiolytic agent.
    Patel JB; Malick JB
    Eur J Pharmacol; 1982 Mar; 78(3):323-33. PubMed ID: 6121711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Naloxone potentiates the effects of subeffective doses of anxiolytic agents in mice.
    Belzung C; Agmo A
    Eur J Pharmacol; 1997 Apr; 323(2-3):133-6. PubMed ID: 9128831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of long-term administration of anxiolytics on reticular-elicited hippocampal rhythmical slow activity.
    Zhu XO; McNaughton N
    Neuropharmacology; 1991 Oct; 30(10):1095-9. PubMed ID: 1684647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antagonism of AMPA receptors produces anxiolytic-like behavior in rodents: effects of GYKI 52466 and its novel analogues.
    Kapus GL; Gacsályi I; Vegh M; Kompagne H; Hegedus E; Leveleki C; Hársing LG; Barkóczy J; Bilkei-Gorzó A; Lévay G
    Psychopharmacology (Berl); 2008 Jun; 198(2):231-41. PubMed ID: 18363046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of anticonvulsive and acute neuroprotective activity of three 2,3-benzodiazepine compounds, GYKI 52466, GYKI 53405, and GYKI 53655.
    Szabados T; Gigler G; Gacsályi I; Gyertyán I; Lévay G
    Brain Res Bull; 2001 Jun; 55(3):387-91. PubMed ID: 11489346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.